Abemaciclib (LY2835219) in Patients With Recurrent Primary Brain Tumors
Last updated on July 2021Recruitment
- Recruitment Status
- Recruiting
- Estimated Enrollment
- Same as current
Summary
- Conditions
- Brain Tumor
- Type
- Interventional
- Phase
- Phase 2
- Design
- Allocation: Non-RandomizedIntervention Model: Crossover AssignmentIntervention Model Description: This is an open-label, non-randomized, phase II trial of single-agent abemaciclib administered at previously defined MTD/RP2D in three cohorts of patients with primary brain tumors.Masking: None (Open Label)Primary Purpose: Treatment
Participation Requirements
- Age
- Between 18 years and 125 years
- Gender
- Both males and females
Description
Not Provided
Not Provided
Tracking Information
- NCT #
- NCT03220646
- Collaborators
- Eli Lilly and Company
- Investigators
- Principal Investigator: Thomas Kaley, MD Memorial Sloan Kettering Cancer Center
Get Well Soon